deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00089791

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Sponsor: Amgen

Conditions Osteoporosis
Interventions Denosumab placebo
Updated 17 times since 2017 Last updated: Nov 4, 2022 Started: Aug 1, 2004 Primary completion: Jun 17, 2008 Completion: Jun 17, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoporosis, this trial is completed. The trial is conducted by Amgen and has accumulated 17 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Sep 2022 — Dec 2022 [monthly]

    Completed PHASE3

  5. May 2022 — Sep 2022 [monthly]

    Completed PHASE3

▶ Show 12 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE3

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jun 2020 — Aug 2020 [monthly]

    Completed PHASE3

  4. Apr 2020 — Jun 2020 [monthly]

    Completed PHASE3

  5. Mar 2019 — Apr 2020 [monthly]

    Completed PHASE3

  6. Nov 2018 — Mar 2019 [monthly]

    Completed PHASE3

  7. Sep 2018 — Nov 2018 [monthly]

    Completed PHASE3

  8. Aug 2018 — Sep 2018 [monthly]

    Completed PHASE3

  9. Jul 2018 — Aug 2018 [monthly]

    Completed PHASE3

  10. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

  11. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE3

  12. Jan 2017 — Jul 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.